New hope for stubborn lymphoma: testing a powerful combo
NCT ID NCT07441954
Summary
This study is testing a new combination of two drugs, pomalidomide and obinutuzumab, for people with slow-growing (indolent) lymphoma that has returned or isn't responding to prior therapy. The first part finds the safest, most effective dose. The second part checks how well the combination works to control the cancer and how safe it is for patients. The goal is to provide a new treatment option for this hard-to-treat situation.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INDOLENT LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.